Research
Hormonal
Intensive glucose control (targeting HbA1c <6.0-6.5%) in Type 2 Diabetes does not significantly reduce cardiovascular events and may increase mortality, whereas intensive control in Type 1 Diabetes shows a sustained legacy benefit on CV outcomes.
Do not assume that achieving very low HbA1c levels (e.g., <6.0%) will prevent heart attacks in Type 2 Diabetes. In fact, aggressive control can be dangerous. Prioritize blood pressure and cholesterol management for cardiovascular protection.
StrongRefutesVERY_HIGH confidence
On the other hand, two large CV outcome trials, ADVANCE... and VADT... showed no significant reduction in CVD risk with intensification of glucose control. A third trial, ACCORD... was prematurely terminated, due to increased mortality in participants randomized to an intensive glucose-control strategy.
Why this rating
Based on multiple large-scale randomized controlled trials (ADVANCE, VADT, ACCORD, UKPDS, DCCT/EDIC).
Source
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Daniel Lorber · Diabetes Metabolic Syndrome and Obesity · 2014
DOI 10.2147/dmso.s61438
narrative_reviewCited 170×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lowering LDL cholesterol with statins reduces major cardiovascular events in Type 2 Diabetes patients, whereas pharmacological interventions to raise HDL cholesterol or lower triglycerides have not shown consistent beneficial effects on cardiovascular risk.Strong
- Lowering blood pressure in Type 2 Diabetes patients reduces the risk of cerebrovascular accidents and congestive heart failure, with ACE inhibitors or ARBs recommended as first-line therapy.Strong
- Intensive lifestyle intervention (caloric restriction + 175 min/week moderate exercise) in overweight/obese T2DM patients reduces cardiovascular risk factors and improves quality of life but does not significantly reduce major cardiovascular events compared to standard diabetes education.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →